NOVARTIS AG

Drug Name	Phase	Indication	Designations	Patent
QVM149	Phase 3	Asthma	-	-
dovitinib	Phase 3	Solid Tumors	-	-
Tamoxifen	Phase 3	Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women	-	-
Anastrozole	Phase 3	Breast Cancer	-	-
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)	Phase 3	Parkinson's Disease	-	-
Canakinumab pre-filled syringe	Phase 3	Acute Gouty Arthritis	-	-
Diclofenac topical sodium gel 1%	Phase 3	Osteoarthritis	-	-
Pelabresib	Phase 3	Myelofibrosis	-	-
valsartan plus hydrochlorothiazide	Phase 3	Hypertension	-	-
Pasireotide LAR	Phase 3	Acromegaly	-	-
QAW039	Phase 3	Asthma	-	-
Lumiracoxib	Phase 3	Knee Osteoarthritis	-	-
Licarbazepine	Phase 3	Bipolar Disorder	-	-
Onasemnogene Abeparvovec-xioi	Phase 3	Spinal Muscular Atrophy Type I	-	-
Canakinumab	Phase 3	Rheumatoid Arthritis	-	-
Enteric-coated Mycophenolate sodium (EC-MPS)	Phase 3	Liver Transplantation	-	-
Valsartan	Phase 3	Hypertension	-	-
Nilotinib	Phase 3	Chronic Myelogenous Leukemia	-	-
FTY720	Phase 3	Multiple Sclerosis	-	-
Everolimus	Phase 3	Tuberous Sclerosis	-	-
Famciclovir	Phase 3	Herpes Labialis	-	-
Certoparin	Phase 3	Renal Dialysis	-	-
Inclisiran	Phase 3	Atherosclerotic Cardiovascular Disease	-	-
asciminib	Phase 3	Chronic Myelogenous Leukemia - Chronic Phase	-	-
Monovalent A/H1N1 influenza vaccine	Phase 3	Pandemic Influenza	-	-
CTL019	Phase 3	Acute Lymphoblastic Leukemia	-	-
imatinib mesylate	Phase 3	Leukemia	-	-
Ranibizumab 0.5 mg	Phase 3	Proliferative Diabetic Retinopathy (PDR)	-	-
RLX030	Phase 3	Acute Heart Failure	-	-
secukinumab (AIN457)	Phase 3	Rheumatoid Arthritis	-	-
Enteric-Coated Mycophenolate Sodium	Phase 3	Prevention of Acute Rejection After Kidney Transplantation	-	-
Pazopanib	Phase 3	Ovarian Cancer	-	-
MenACWY-CRM	Phase 3	Meningococcal Disease	-	-
LCQ908	Phase 3	Familial Chylomicronemia Syndrome (FCS)	-	-
Imatinib	Phase 3	Chronic Myelogenous Leukemia in Chronic Phase	-	-
Octreotide LAR	Phase 3	Acromegaly	-	-
Agomelatine (AGO178C)	Phase 3	Major Depressive Disorder	-	-
osilodrostat	Phase 3	Cushings Disease	-	-
Ofatumumab	Phase 3	Relapsing Multiple Sclerosis	-	-
Letrozole	Phase 3	Breast Cancer	-	-
LCZ696	Phase 3	Hypertension	-	-
Meningococcal ACWY conjugate vaccine	Phase 3	Bacterial Meningitis	-	-
Olmesartan	Phase 3	Essential Hypertension	-	-
Secukinumab 300 mg	Phase 3	Chronic Scalp Psoriasis	-	-
Salmeterol 50 μg	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
iptacopan	Phase 3	IC-MPGN	-	-
rMenB+OMV NZ	Phase 3	Prevention of the Meningococcal Disease	-	-
valsartan/amlodipine	Phase 3	Hypertension	-	-
LNP023	Phase 3	Paroxysmal Nocturnal Hemoglobinuria (PNH)	-	-
Ruxolitinib	Phase 3	Cytokine Storm (Covid-19)	-	-
Ligelizumab	Phase 3	Chronic Spontaneous Urticaria	-	-
AMN107	Phase 3	Leukemia, Myeloid, Chronic	-	-
QAB149	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Tobramycin inhalation powder	Phase 3	Pulmonary Infections	-	-
Bosutinib	Phase 3	Chronic Myelogenous Leukemia	-	-
Influenza virus vaccine	Phase 3	Influenza	-	-
Enalapril	Phase 3	Hypertension	-	-
Paclitaxel	Phase 3	Breast Cancer	-	-
secukinumab 150 mg	Phase 3	Moderate to Severe Chronic Plaque-type Psoriasis	-	-
Rivastigmine	Phase 3	Vascular Dementia	-	-
Sitagliptin	Phase 3	Diabetes Mellitus, Type 2	-	-
Indacaterol 300 μg	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Formoterol	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Mycophenolate mofetil (MMF)	Phase 3	Kidney Transplantation	-	-
Secukinumab (75 mg)	Phase 3	Psoriatic Arthritis	-	-
Remibrutinib	Phase 3	Chronic Spontaneous Urticaria	-	-
Formoterol (12 µg b.i.d.)	Phase 3	Pulmonary Disease, Chronic Obstructive	-	-
Nilotinib (AMN107)	Phase 3	Gastrointestinal Stromal Tumor (GIST)	-	-
NVA237	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Prednisone	Phase 3	Renal Transplantation	-	-
QVA149	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
vildagliptin	Phase 3	Diabetes Mellitus, Type 2	-	-
ranibizumab	Phase 3	Neovascular Age-related Macular Degeneration	-	-
TIVc	Phase 3	Influenza	-	-
Omalizumab	Phase 3	Asthma	-	-
Fingolimod	Phase 3	Multiple Sclerosis	-	-
secukinumab	Phase 3	Juvenile Psoriatic Arthritis	-	-
Tegaserod	Phase 3	Dyspepsia	-	-
aliskiren	Phase 3	Hypertension	-	-
Indacaterol	Phase 3	Asthma	-	-
Zoledronic acid	Phase 3	Breast Cancer With Bone Metastasis	-	-
Tiotropium	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Midostaurin	Phase 2	Acute Myeloid Leukemia	-	-
eltrombopag	Phase 2	Immune Thrombocytopenic Purpura (ITP)	-	-
Iptacopan (LNP023)	Phase 2	Age-Related Macular Degeneration	-	-
DFV890	Phase 2	Symptomatic Knee Osteoarthritis	-	-
CFZ533	Phase 2	Sjögren Syndrome	-	-
AFQ056	Phase 2	Dyskinesias	-	-
Trametinib	Phase 2	Melanoma and Brain Metastases	-	-
Seasonal Influenza Vaccine	Phase 2	Influenza	-	-
RAD001	Phase 2	Carcinoma	-	-
epothilone b	Phase 2	Colorectal Neoplasms	-	-
Nidufexor	Phase 2	Diabetic Nephropathy	-	-
AIN457	Phase 2	Plaque-type Psoriasis	-	-
DNK333 5 mg	Phase 2	Pruritus in Patients With Atopic Dermatitis	-	-
ECMPS-IEM	Phase 2	Detection Accuracy	-	-
LOU064	Phase 2	Chronic Spontaneous Urticaria	-	-
LDE225	Phase 2	Medulloblastoma	-	-
TKI258	Phase 2	Melanoma	-	-
JDQ443	Phase 2	Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation	-	-
AEB071	Phase 2	Kidney Transplantation	-	-
ramipril	Phase 2	Heart Failure	-	-
LYS006 20 mg	Phase 2	Inflammatory Acne	-	-
Capecitabine	Phase 2	Breast Cancer	-	-
AEE788	Phase 2	Glioblastoma Multiforme	-	-
CDZ173	Phase 2	Primary Sjögren's Syndrome	-	-
[177Lu]Lu-PSMA-617	Phase 2	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	-	-
AAE581	Phase 2	Osteoporosis	-	-
Trivalent influenza virus vaccine (TIV)	Phase 2	Human Influenza	-	-
CAD106	Phase 2	Alzheimer Disease	-	-
LDK378	Phase 2	Non-Small-Cell Lung Cancer	-	-
Pimecrolimus	Phase 2	Keratoconjunctivitis Sicca	-	-
BGG492	Phase 2	Adrenocortical Adenoma	-	-
TIV	Phase 2	Human Influenza	-	-
Serelaxin	Phase 2	Acute Heart Failure	-	-
Investigational new drug, company code: BGG492	Phase 2	Seizures	-	-
Dabrafenib	Phase 2	Neoplasms, Brain	-	-
rapcabtagene autoleucel	Phase 2	Lupus Erythematosus, Systemic	-	-
LIK066	Phase 2	Polycystic Ovary Syndrome	-	-
LEE011	Phase 2	Tumors With CDK4/6 Pathway Activation	-	-
deferasirox	Phase 2	Non-transfusion Dependent Thalassemia	-	-
CMK389	Phase 2	Pulmonary Sarcoidosis	-	-
rMenB	Phase 2	Meningococcal Disease	-	-
Ribociclib	Phase 2	Breast Cancer	-	-
crizanlizumab	Phase 2	Sickle Cell Disease (SCD)	-	-
Alpelisib	Phase 2	Breast Neoplasms	-	-
ACZ885	Phase 2	Pulmonary Sarcoidosis	-	-
Bendamustine	Phase 2	Chronic Lymphocytic Leukemia (CLL)	-	-
ranibizumab 0.5mg	Phase 2	Choroidal Neovascularisation	-	-
PDR001	Phase 2	Small Cell Lung Cancer	-	-
Mometasone furoate	Phase 2	Asthma	-	-
VHB937	Phase 2	Alzheimer's Disease	-	-
Sunitinib	Phase 2	Carcinoma, Renal Cell	-	-
amlodipine	Phase 2	Hypertension	-	-
BYM338	Phase 2	Sporadic Inclusion Body Myositis	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

NOVARTIS AG

Market Overview

NVSEF News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals